ARCH Venture Fund IX, L.P. - 31 Dec 2024 SCHEDULE 13G/A Report for Beam Therapeutics Inc. Common Stock par value $0.01 per share (BEAM)

Filing Manager
ARCH Venture Fund IX, L.P.
Reporting Manager
Robert Nelsen
Security
Beam Therapeutics Inc. Common Stock par value $0.01 per share
Symbol
BEAM
Shares outstanding
82,156,196 shares
Disclosed Ownership
4,600,747 shares
Ownership
5.6%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 16:55:02 UTC
Date of event
31 Dec 2024
Next filing
15 May 2025
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ARCH Venture Fund IX, L.P. 5.5% 4,540,132 0 4,540,132 ARCH Venture Partners IX, L.P. its General Partner
ARCH Venture Fund IX Overage, L.P. 5.5% 4,540,132 0 4,540,132 ARCH Venture Partners IX Overage, L.P. its General Partner
ARCH Venture Partners IX, L.P. 5.5% 4,540,132 0 4,540,132 ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX Overage, L.P. 5.5% 4,540,132 0 4,540,132 ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX, LLC 5.5% 4,540,132 0 4,540,132 /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Keith Crandell 5.5% 4,557,862 17,730 4,540,132 /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Clinton Bybee 5.5% 4,550,630 10,498 4,540,132 /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Robert Nelsen 5.6% 4,600,747 60,615 4,540,132 /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen